Sugi Predict

Sugi Predict / Compounds / SCHEMBL8040438

SCHEMBL8040438

SCHEMBL8040438

CCOC(=O)c1ccc(C2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.54
▸ GPR119 Q8TDV5 8/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ MAPT P10636 2/20 0.52
▸ TP53 P04637 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ FDFT1 P37268 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.47
▸ THRB P10828 1/20 0.47
▸ HPGD P15428 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31386285 0.94 PDE4B (0.53) NAMPTGPR119NPSR1KMT2AALDH1A1
SCHEMBL20046172 0.89 GPR119 (0.48) NAMPTGPR119NPSR1KMT2AALDH1A1
SCHEMBL15952633 0.88 ATM (0.47) NAMPTGPR119NPSR1KMT2AALDH1A1
SCHEMBL1274282 0.86 TP53 (0.55) NAMPTGPR119NPSR1KMT2AALDH1A1
SCHEMBL1198897 0.86 NAMPT (0.60) NAMPTGPR119KMT2AALDH1A1MAPT
SCHEMBL17366247 0.85 GPR119 (0.61) NAMPTGPR119LMNAGAASMN1; SMN2
SCHEMBL10243179 0.85 NAMPT (0.58) NAMPTGPR119GAASMN1; SMN2MAPT
SCHEMBL1375168 0.83 GPR119 (0.61) GPR119NPSR1MAPTPOLBATM
SCHEMBL6705316 0.83 L3MBTL1 (0.51) GPR119NPSR1KMT2AALDH1A1MEN1
SCHEMBL14711416 0.83 GPR119 (0.52) NAMPTGPR119NPSR1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018123-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-01-18 — — US disclosed
US-20240018123-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-01-18 — — US disclosed
US-20240018123-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-01-18 — — US disclosed
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 — — US disclosed
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 — — US disclosed
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 — — US disclosed
US-11485745-B2 Amido spirocyclic amide and sulfonamide derivatives VALO HEALTH, INC. (US) 2022-11-01 — — US disclosed
EP-4066896-A1 G9A INHIBITOR RIKEN (JP) 2022-10-05 — — EP disclosed
US-20210171545-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES VALO HEALTH, INC. 2021-06-10 — — US disclosed
WO-2021106988-A1 G9a INHIBITOR 杏林製薬株式会社 2021-06-03 — — WO disclosed
CN-104520290-B Amido spirocyclic amide and sulfonamide derivatives 基因科技股份有限公司 2020-10-09 — — CN disclosed
US-10730889-B2 Amido spirocyclic amide and sulfonamide derivatives FORMA TM, LLC (US) 2020-08-04 — — US disclosed
US-20180339998-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES Valo Health, LLC 2018-11-29 — — US disclosed
US-9822129-B2 Amido spirocyclic amide and sulfonamide derivatives GENENTECH, INC. (US) 2017-11-21 — — US disclosed
US-20170216262-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES VALO EARLY DISCOVERY, INC. 2017-08-03 — — US disclosed
EP-2820008-B1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES GENENTECH INC (US) 2016-12-14 — — EP disclosed
US-20160002266-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES GENENTECH, INC. (US) 2016-01-07 — — US disclosed
US-8507512-B2 Soluble guanylate cyclase activators MERCK SHARP & DOHME CORP. (US) 2013-08-13 — — US disclosed
US-20100216764-A1 Soluble Guanylate Cyclase Activators MERCK SHARP & DOHME LLC 2010-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002266-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES STS, AADAC, SULT2A1 NAMPT 49/4885GPR119 1330/4885NPSR1 461/4885
US-20170216262-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES STS, AADAC, SULT2A1 NAMPT 49/4885GPR119 1330/4885NPSR1 461/4885
US-20210171545-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES STS, AADAC, SULT2A1 NAMPT 49/4885GPR119 1330/4885NPSR1 461/4885
US-20230127046-A1 G9a INHIBITOR EZH2, BMI1, DOT1L NAMPT 4182/4885GPR119 532/4885NPSR1 4614/4885
US-11485745-B2 Amido spirocyclic amide and sulfonamide derivatives STS, AADAC, SULT2A1 NAMPT 49/4885GPR119 1330/4885NPSR1 461/4885
US-20180339998-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES STS, AADAC, SULT2A1 NAMPT 49/4885GPR119 1330/4885NPSR1 461/4885
US-20240018123-A1 COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG NAMPT 2690/4885GPR119 28/4885NPSR1 173/4885
US-10730889-B2 Amido spirocyclic amide and sulfonamide derivatives STS, AADAC, SULT2A1 NAMPT 49/4885GPR119 1330/4885NPSR1 461/4885
US-20100216764-A1 Soluble Guanylate Cyclase Activators GUCY1B1, GUCY1A1, GUCY1A2 NAMPT 4227/4885GPR119 46/4885NPSR1 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.